EL7.AI
StocksMediumUpdated•Originally published 29 July 2026•Updated 29 July 2026•
1 min read

Humana Targets Margin Recovery by 2028 Following Analyst Upgrade and Q2 Beat

Key Facts

1Evercore ISI upgraded Humana (HUM) to Outperform at a stock price of $367.18.
2Humana reported adjusted earnings of $7.61 per share, exceeding expectations by 22.4%.
3Adjusted revenues grew 26.2% to $40.9 billion, driven by significant medical membership growth.

As health insurers navigate structural shifts in profitability, Evercore ISI upgraded Humana (HUM) to Outperform with a price of $367.18. The upgrade coincides with robust Q2 2026 results, where the company delivered adjusted earnings of $7.61 per share, beating estimates by 22.4%. Adjusted revenue climbed 26.2% to $40.9 billion, supported by a 20.7% surge in medical membership to 17.9 million members.

Despite top-line growth, new data reveals significant margin compression, with pre-tax profit margins dropping to 1.8% in Q2 2026 from 6.7% in 2020. Per market data, the benefit ratio climbed above 91%, highlighting the impact of rising medical costs. To counter this, management has established a strategic target to recover pre-tax margins to 3% by 2028 through improved Medicare Advantage plan quality ratings and selective market exits.

Humana's stock (HUM) closed at $388.71 on July 28, 2026, as investors weigh the long-term recovery plan against current cost headwinds. Market participants are now monitoring the execution of cost-reduction initiatives and the performance of the CenterWell segment. With full-year guidance maintained at a minimum of $9 per share, the focus remains on whether these strategic shifts can restore historical profitability levels.